ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00. Following the completion of the sale, the vice president owned 77,390 shares of the company’s stock, valued at $6,333,597.60. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total value of $41,015.00.
• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.16, for a total value of $39,080.00.

ANI Pharmaceuticals Trading Down 0.7%

NASDAQ ANIP opened at $80.55 on Wednesday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a twelve month low of $62.60 and a twelve month high of $99.50. The firm has a market capitalization of $1.83 billion, a PE ratio of 20.39 and a beta of 0.43. The stock’s 50 day moving average is $81.53 and its 200 day moving average is $79.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same quarter in the prior year, the company earned $1.70 earnings per share. The firm’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV bought a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth $28,000. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the second quarter valued at $50,000. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on ANIP. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Guggenheim reissued a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.